Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.61 |
| ▸ | KDR | P35968 | 3/20 | 0.60 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | RET | P07949 | 1/20 | 0.60 |
| ▸ | KIF5B | P33176 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | KDM1A | O60341 | 4/20 | 0.52 |
| ▸ | BRAF | P15056 | 7/20 | 0.50 |
| ▸ | RAF1 | P04049 | 4/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012180 | 0.80 | KDR (0.73) | KDREGFRRETKIF5BLCK | |
| SCHEMBL4375169 | 0.79 | KDM1A (0.76) | KDREGFRRETKIF5BLCK | |
| SCHEMBL15516134 | 0.76 | KIT (1.00) | KITKDREGFRRETKIF5B | |
| SCHEMBL1012192 | 0.76 | EGFR (0.57) | KITKDREGFRRETKIF5B | |
| SCHEMBL7209616 | 0.75 | KDR (1.00) | KDREGFRRETKIF5BLCK | |
| SCHEMBL1013510 | 0.74 | RET (0.65) | KDREGFRRETKIF5BLCK | |
| SCHEMBL1013313 | 0.74 | RET (0.65) | KDREGFRRETKIF5BLCK | |
| SCHEMBL18158551 | 0.74 | KDM1A (0.62) | KITKDREGFRRETKIF5B | |
| SCHEMBL5206218 | 0.74 | KDR (0.74) | KITKDREGFRRETKIF5B | |
| SCHEMBL1483638 | 0.73 | EGFR (0.71) | KDREGFRRETKIF5BLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2023926-B1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | Bayer Pharma AG (DE) | 2011-10-12 | — | — | EP | disclosed |
| EP-2023926-B1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | Bayer Pharma AG (DE) | 2011-10-12 | — | — | EP | disclosed |
| US-20090306103-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306103-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306103-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-2023926-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | Bayer HealthCare AG (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008048375-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008048375-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306103-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | MKI67, FLT4, VEGFA | KIT 242/4885KDR 6/4885EGFR 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.